Overview

Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Antibodies, Monoclonal
Omalizumab